R 138727 (BioDeep_00000735732)
代谢物信息卡片
(2Z)-2-[1-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-sulfanylpiperidin-3-ylidene]acetic acid
化学式: C18H20FNO3S (349.1147862)
中文名称: 普拉格雷代谢物
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC1C(=O)C(C2=CC=CC=C2F)N3CCC(C(=CC(=O)O)C3)S
InChI: InChI=1S/C18H20FNO3S/c19-14-4-2-1-3-13(14)17(18(23)11-5-6-11)20-8-7-15(24)12(10-20)9-16(21)22/h1-4,9,11,15,17,24H,5-8,10H2,(H,21,22)/b12-9-
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:172573
- PubChem: 10405534
- ChEMBL: CHEMBL3526431
- CAS: 204204-73-9
- CAS: 239466-74-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mitsuhiro Nishihara. Inhibitory Effect of Vonoprazan on the Metabolism of [14C]Prasugrel in Human Liver Microsomes.
European journal of drug metabolism and pharmacokinetics.
2019 Oct; 44(5):713-717. doi:
10.1007/s13318-019-00554-y. [PMID: 30993551] - Grace E Martin, Amanda M Pugh, Ryan Moran, Rose Veile, Lou Ann Friend, Timothy A Pritts, Amy T Makley, Charles C Caldwell, Michael D Goodman. Microvesicles generated following traumatic brain injury induce platelet dysfunction via adenosine diphosphate receptor.
The journal of trauma and acute care surgery.
2019 04; 86(4):592-600. doi:
10.1097/ta.0000000000002171. [PMID: 30614923] - Tomoko Hasunuma, Hiroyuki Fukase, Atsuhiro Miyazaki, Yasuhiro Nishikawa. Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects.
Clinical drug investigation.
2017 Jul; 37(7):679-685. doi:
10.1007/s40261-017-0525-0. [PMID: 28417436] - Kazuo Umemura, Yasuhiko Ikeda, Nobuko Matsushima, Kazunao Kondo. Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in Combination With Aspirin in Healthy Japanese Subjects.
Clinical pharmacology in drug development.
2017 Jul; 6(4):398-407. doi:
10.1002/cpdd.308. [PMID: 27652589] - Sreekanth Kakarla, Peda Varma Datla, Geetha Kodali, Ganapaty Seru. Analysis of prasugrel active metabolite R-138727 in human plasma: a sensitive, highly selective and fast LC-MS/MS method.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 May; 1020(?):103-10. doi:
10.1016/j.jchromb.2016.03.035. [PMID: 27038402] - Hae-Sun Jeon, Mi-Jo Kim, Hee-Youn Choi, Yo-Han Kim, Eun-Hwa Kim, A-Reum Kim, Hyun-Jung Park, Kyun-Seop Bae, Hyeong-Seok Lim. Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers.
Clinical therapeutics.
2015 Mar; 37(3):563-73. doi:
10.1016/j.clinthera.2015.01.010. [PMID: 25697420] - Licia Totani, Giuseppe Dell'Elba, Nicola Martelli, Angelomaria Di Santo, Antonio Piccoli, Concetta Amore, Virgilio Evangelista. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse.
Thrombosis and haemostasis.
2012 Jun; 107(6):1130-40. doi:
10.1160/th11-12-0867. [PMID: 22436970] - Ojikumar Lukram, Mukund Zarapkar, Chandan Kumar Jha, Shivaji Parmar, Keshav S Tomar, Amit Hande. Electrospray ionization LC-MS/MS validated method for the determination of the active metabolite (R-138727) of prasugrel in human plasma and its application to a bioequivalence study.
Drug testing and analysis.
2012 Feb; 4(2):158-66. doi:
10.1002/dta.264. [PMID: 21438161] - Katsunobu Hagihara, Miho Kazui, Hidenori Ikenaga, Toshihiko Nanba, Kiichi Fusegawa, Takashi Izumi, Toshihiko Ikeda, Atsushi Kurihara. The intestine as an important contributor to prasugrel active metabolite formation in vivo.
Drug metabolism and disposition: the biological fate of chemicals.
2011 Apr; 39(4):565-70. doi:
10.1124/dmd.110.035956. [PMID: 21189331] - P C J Armstrong, P D Leadbeater, M V Chan, N S Kirkby, J A Jakubowski, J A Mitchell, T D Warner. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.
Journal of thrombosis and haemostasis : JTH.
2011 Mar; 9(3):552-61. doi:
10.1111/j.1538-7836.2010.04160.x. [PMID: 21143373] - Joseph A Jakubowski, Chunmei Zhou, Blaine Egan, Maggie Wells, Maya Kotob-Yahfoufi, Atsuhiro Sugidachi, Jeffrey R Dahlen. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
Platelets.
2011; 22(8):619-25. doi:
10.3109/09537104.2011.579203. [PMID: 21639823] - David S Small, Prajakti Kothare, Eunice Yuen, D Richard Lachno, Ying G Li, Kenneth J Winters, Nagy A Farid, Lan Ni, Joseph A Jakubowski, Daniel E Salazar, Vivian T Thieu, Christopher D Payne. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects.
European journal of clinical pharmacology.
2010 Feb; 66(2):127-35. doi:
10.1007/s00228-009-0737-1. [PMID: 19888568] - K Hagihara, M Kazui, H Ikenaga, T Nanba, K Fusegawa, M Takahashi, A Kurihara, O Okazaki, N A Farid, T Ikeda. Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.
Xenobiotica; the fate of foreign compounds in biological systems.
2009 Mar; 39(3):218-26. doi:
10.1080/00498250802650077. [PMID: 19280520] - David S Small, Rebecca E Wrishko, C Steven Ernest, Lan Ni, Kenneth J Winters, Nagy A Farid, Ying G Li, Daniel E Salazar, Christopher D Payne. Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial.
Drugs & aging.
2009; 26(9):781-90. doi:
10.2165/11315780-000000000-00000. [PMID: 19728751] - Heather M Judge, Robert J Buckland, Atsuhiro Sugidachi, Joseph A Jakubowski, Robert F Storey. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Platelets.
2008 Mar; 19(2):125-33. doi:
10.1080/09537100701694144. [PMID: 18297550] - Nagy A Farid, Richard L Smith, Todd A Gillespie, T James Rash, Patrick E Blair, Atsushi Kurihara, Mark J Goldberg. The disposition of prasugrel, a novel thienopyridine, in humans.
Drug metabolism and disposition: the biological fate of chemicals.
2007 Jul; 35(7):1096-104. doi:
10.1124/dmd.106.014522. [PMID: 17403916] - Andrew L Frelinger, Joseph A Jakubowski, Youfu Li, Marc R Barnard, Marsha L Fox, Matthew D Linden, Atsuhiro Sugidachi, Kenneth J Winters, Mark I Furman, Alan D Michelson. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
Thrombosis and haemostasis.
2007 Jul; 98(1):192-200. doi:
10.1160/th07-01-0010. [PMID: 17598013] - Enaksha R Wickremsinhe, Ye Tian, Kenneth J Ruterbories, Elizabeth M Verburg, Govinda J Weerakkody, Atsushi Kurihara, Nagy A Farid. Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method.
Drug metabolism and disposition: the biological fate of chemicals.
2007 Jun; 35(6):917-21. doi:
10.1124/dmd.106.014530. [PMID: 17353347]